{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:20:58Z","timestamp":1790403658554,"version":"4.1.0"},"reference-count":120,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The constantly growing number of people suffering from bacterial, viral, or fungal infections, parasitic diseases, and cancers prompts the search for innovative methods of disease prevention and treatment, especially based on vaccines and targeted therapy. An additional problem is the global threat to humanity resulting from the increasing resistance of bacteria to commonly used antibiotics. Conventional vaccines based on bacteria or viruses are common and are generally effective in preventing and controlling various infectious diseases in humans. However, there are problems with the stability of these vaccines, their transport, targeted delivery, safe use, and side effects. In this context, experimental phage therapy based on viruses replicating in bacterial cells currently offers a chance for a breakthrough in the treatment of bacterial infections. Phages are not infectious and pathogenic to eukaryotic cells and do not cause diseases in human body. Furthermore, bacterial viruses are sufficient immuno-stimulators with potential adjuvant abilities, easy to transport, and store. They can also be produced on a large scale with cost reduction. In recent years, they have also provided an ideal platform for the design and production of phage-based vaccines to induce protective host immune responses. The most promising in this group are phage-displayed vaccines, allowing for the display of immunogenic peptides or proteins on the phage surfaces, or phage DNA vaccines responsible for expression of target genes (encoding protective antigens) incorporated into the phage genome. Phage vaccines inducing the production of specific antibodies may in the future protect us against infectious diseases and constitute an effective immune tool to fight cancer. Moreover, personalized phage therapy can represent the greatest medical achievement that saves lives. This review demonstrates the latest advances and developments in the use of phage vaccines to prevent human infectious diseases; phage-based therapy, including clinical trials; and personalized treatment adapted to the patient\u2019s needs and the type of bacterial infection. It highlights the advantages and disadvantages of experimental phage therapy and, at the same time, indicates its great potential in the treatment of various diseases, especially those resistant to commonly used antibiotics. All the analyses performed look at the rich history and development of phage therapy over the past 100 years.<\/jats:p>","DOI":"10.3390\/ph14040331","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:48:29Z","timestamp":1617623309000},"page":"331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Bacteriophages as Potential Tools for Use in Antimicrobial Therapy and Vaccine Development"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-1218","authenticated-orcid":false,"given":"Beata","family":"Zalewska-Pi\u0105tek","sequence":"first","affiliation":[{"name":"Department of Molecular Biotechnology and Microbiology, Chemical Faculty, Gda\u0144sk University of Technology, Narutowicza 11\/12, 80-233 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Pi\u0105tek","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Microbiology, Chemical Faculty, Gda\u0144sk University of Technology, Narutowicza 11\/12, 80-233 Gda\u0144sk, Poland"},{"name":"BioTechMed Center, Gda\u0144sk University of Technology, Narutowicza 11\/12, 80-233 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"ref_1","unstructured":"ICD-10-World Health Organization (2019, November 01). International Statistical Classification of Diseases and Related Health Problems. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/246208."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fmicb.2010.00134","article-title":"A brief history of the antibiotic era: Lessons learned and challenges for the future","volume":"1","author":"Aminov","year":"2010","journal-title":"Front. Microbiol."},{"key":"ref_3","unstructured":"Tacconelli, E., and Magrini, N. (2017, February 27). Global Priority List of Antiobiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available online: www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Abedon, S.T. (2018). Bacteriophage Clinical Use as Antibacterial \u201cDrugs\u201d: Utility and Precedent, ASM Press.","DOI":"10.1128\/9781555819705.ch19"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Abedon, S.T. (2019). Phage-antibiotic combination treatments: Antagonistic impacts of antibiotics on the pharmacodynamics of phage therapy?. Antibiotics, 8.","DOI":"10.3390\/antibiotics8040182"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Laanto, E., M\u00e4kel\u00e4, K., Hoikkala, V., Ravantti, J.J., and Sundberg, L.-R. (2020). Adapting a phage to combat phage resistance. Antibiotics, 9.","DOI":"10.3390\/antibiotics9060291"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Henriksen, K., R\u00f8rbo, N., Rybtke, M.L., Martinet, M.G., Tolker-Nielsen, T., H\u00f8iby, N., Middelboe, M., and Ciofu, O.P. (2019). Aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage\u2013ciprofloxacin combination. Pathog. Dis., 77.","DOI":"10.1093\/femspd\/ftz011"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2018.12.004","article-title":"Antimicrobial assessment of phage therapy using a porcine model of biofilm infection","volume":"557","author":"Milho","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.micpath.2019.01.032","article-title":"Isolation and characterization of a bacteriophage and its potential to disrupt multi-drug resistant Pseudomonas aeruginosa biofilms","volume":"128","author":"Yuan","year":"2019","journal-title":"Microb. Pathog."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/alr.22046","article-title":"Bacteriophage effectively kills multidrug resistantStaphylococcus aureusclinical isolates from chronic rhinosinusitis patients","volume":"8","author":"Zhang","year":"2017","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ijantimicag.2018.09.006","article-title":"Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus","volume":"52","author":"Tkhilaishvili","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1534734619835115","article-title":"Bacteriophage therapy of chronic nonhealing wound: Clinical study","volume":"18","author":"Gupta","year":"2019","journal-title":"Int. J. Low. Extremity Wounds"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3389\/fmicb.2018.01832","article-title":"Adapted bacteriophages for treating urinary tract infections","volume":"9","author":"Ujmajuridze","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Schooley, R.T., Biswas, B., Gill, J.J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J.J., Reed, S.L., Rohwer, F., and Benler, S. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00954-17"},{"key":"ref_16","first-page":"2631","article-title":"Early clinical experience of bacteriophage therapy in 3 lung transplant recipients","volume":"19","author":"Aslam","year":"2019","journal-title":"Arab. Archaeol. Epigr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.addr.2018.12.013","article-title":"Phage-based vaccines","volume":"145","author":"Bao","year":"2019","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Mora, A., Hern\u00e1ndez-P\u00e9rez, J., Iqbal, H.M.N., Rito-Palomares, M., and Benavides, J. (2020). Bacteriophage-Based vaccines: A potent approach for antigen delivery. Vaccines, 8.","DOI":"10.3390\/vaccines8030504"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrmicro3564","article-title":"A century of the phage: Past, present and future","volume":"13","author":"Salmond","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4161\/bact.1.2.14590","article-title":"Pros and cons of phage therapy","volume":"1","author":"Abedon","year":"2011","journal-title":"Bacteriophage"},{"key":"ref_22","first-page":"1","article-title":"Phage display as a promising approach for vaccine development","volume":"23","author":"Bakhshinejad","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yerushalmy, O., Khalifa, L., Gold, N., Rakov, C., Alkalay-Oren, S., Adler, K., Ben-Porat, S., Kraitman, R., Gronovich, N., and Ginat, K.S. (2020). The Israeli Phage Bank (IPB). Antibiotics, 9.","DOI":"10.3390\/antibiotics9050269"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4161\/bact.1.3.16736","article-title":"The bactericidal action of the waters of the Jamuna and Ganges rivers on Cholera microbes. Ann. Inst. Pasteur 10:511\u2013523 (1896)","volume":"1","author":"Hankin","year":"2011","journal-title":"Bacteriophage"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.45.3.649-659.2001","article-title":"Bacteriophage therapy","volume":"45","author":"Sulakvelidze","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","first-page":"67","article-title":"Bacteriophages and phage therapy in pediatric practice","volume":"4","author":"Samsygina","year":"1984","journal-title":"Pediatriia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(01)20383-3","article-title":"An investigation on the nature of ultra-microscopic viruses","volume":"186","author":"Twort","year":"1915","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.resmic.2007.07.005","article-title":"On an invisible microbe antagonistic toward dysenteric bacilli: Brief note by Mr. F. D\u2019Herelle, presented by Mr. Roux","volume":"158","author":"Service","year":"2007","journal-title":"Res. Microbiol."},{"key":"ref_29","first-page":"373","article-title":"Sur un microbe invisible antagoniste des bacilles dysen-t\u00e9riques","volume":"165","year":"1917","journal-title":"C. R. Acad. Sci. Paris"},{"key":"ref_30","unstructured":"Summers, W.C. (1999). Felix d\u2019Herelle and the Origins of Molecular Biology, Yale University Press."},{"key":"ref_31","first-page":"619","article-title":"An address on bacteriophagy and recovery from infectious diseases","volume":"24","year":"1931","journal-title":"Can. Med. Assoc. J."},{"key":"ref_32","first-page":"155","article-title":"Die Bedeutung der \u00dcbermikroskopie f\u00fcr die Virusforschung","volume":"1","author":"Ruska","year":"1939","journal-title":"Arch. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jama.1934.72750490003007","article-title":"Bacteriophage therapy. Review of the principles and results of the use of bacteriophage in the treatment of infections","volume":"23","author":"Eaton","year":"1934","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.1941.62820200013011","article-title":"The bacteriophage","volume":"116","author":"Krueger","year":"1941","journal-title":"J. Am. Med Assoc."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11262-020-01735-7","article-title":"Approaches to optimize therapeutic bacteriophage and bacteriophage-derived products to combat bacterial infections","volume":"56","author":"Reuter","year":"2020","journal-title":"Virus Genes"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/265687a0","article-title":"Nucleotide sequence of bacteriophage \u03a6174 DNA","volume":"265","author":"Sanger","year":"1977","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0378-1119(88)90495-7","article-title":"Antibody-selectable filamentous fd phage vectors: Affinity purification of target genes","volume":"73","author":"Parmley","year":"1988","journal-title":"Gene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1126\/science.2531466","article-title":"Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda","volume":"246","author":"Huse","year":"1989","journal-title":"Science"},{"key":"ref_40","first-page":"552","article-title":"Phage antibodies: Filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nat. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1016\/S0021-9258(18)68927-6","article-title":"Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage","volume":"263","author":"Lal","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_42","first-page":"267","article-title":"Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results","volume":"31","author":"Slopek","year":"1983","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_43","first-page":"293","article-title":"Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results","volume":"31","author":"Slopek","year":"1983","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_44","first-page":"317","article-title":"Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in a further 150 cases","volume":"32","author":"Slopek","year":"1984","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_45","first-page":"219","article-title":"Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases","volume":"33","author":"Slopek","year":"1985","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_46","first-page":"241","article-title":"Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children","volume":"33","author":"Slopek","year":"1985","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_47","first-page":"261","article-title":"Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections","volume":"33","author":"Slopek","year":"1985","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-394438-2.00003-7","article-title":"Clinical aspects of phage therapy","volume":"83","author":"Borysowski","year":"2012","journal-title":"Adv. Virus Res."},{"key":"ref_49","first-page":"1515","article-title":"Phage therapy: Combating infections with potential for evolving from merely a treatment for complications to targeting diseases","volume":"7","author":"Fortuna","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"G\u00f3rski, A., Mi\u0119dzybrodzki, R., \u0141obocka, M., G\u0142owacka-Rutkowska, A., Bednarek, A., Borysowski, J., Jo\u0144czyk-Matysiak, E., \u0141usiak-Szelachowska, M., Weber-D\u0105browska, B., and Bagi\u0144ska, N. (2018). Phage therapy: What have we learned?. Viruses, 10.","DOI":"10.3390\/v10060288"},{"key":"ref_51","first-page":"459","article-title":"Phage therapy: Current status and perspectives","volume":"40","author":"Borysowski","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: Harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Goracci, M., Pignochino, Y., and Marchi\u00f2, S. (2020). Phage display-based nanotechnology applications in cancer immunotherapy. Molecules, 25.","DOI":"10.3390\/molecules25040843"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2041","DOI":"10.1002\/rmv.2041","article-title":"The dawn of phage therapy","volume":"29","author":"Rehman","year":"2019","journal-title":"Rev. Med Virol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hobernik, D., and Bros, M. (2018). DNA Vaccines\u2014How far from clinical use?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113605"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.11599\/germs.2013.1034","article-title":"DNA vaccines: Roles against diseases","volume":"3","author":"Khan","year":"2013","journal-title":"Germs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J. Biotechnol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e10142","DOI":"10.1002\/btm2.10142","article-title":"Phage display as a tool for vaccine and immunotherapy development","volume":"5","author":"Hess","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12896-018-0419-0","article-title":"Optimized DNA electroporation for primary human T cell engineering","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Biotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"29.20.1","DOI":"10.1002\/cpps.50","article-title":"Generation of high-specificity antibodies against membrane proteins using dna-gold micronanoplexes for gene gun immunization","volume":"91","author":"Hansen","year":"2018","journal-title":"Curr. Protoc. Protein Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1021\/acs.biomac.5b01226","article-title":"Reiterated targeting peptides on the nanoparticle surface significantly promote targeted vascular endothelial growth factor gene delivery to stem cells","volume":"16","author":"Wang","year":"2015","journal-title":"Biomacromolecules"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0928-8244(03)00344-4","article-title":"Bacteriophage-mediated nucleic acid immunisation","volume":"40","author":"Clark","year":"2004","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.vaccine.2003.10.047","article-title":"Genetic immunisation against hepatitis B using whole bacteriophage \u03bb particles","volume":"22","author":"March","year":"2004","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1574-695X.2010.00763.x","article-title":"Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B","volume":"61","author":"Clark","year":"2011","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11262-014-1070-z","article-title":"Enhanced cell immune responses to hepatitis c virus core by novel heterologous DNA prime\/lambda nanoparticles boost in mice","volume":"49","author":"Saeedi","year":"2014","journal-title":"Virus Genes"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jviromet.2009.11.008","article-title":"Evaluation of humoral and cellular immune responses against HSV-1 using genetic immunization by filamentous phage particles: A comparative approach to conventional DNA vaccine","volume":"163","author":"Hashemi","year":"2010","journal-title":"J. Virol. Methods"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.apjtb.2017.06.001","article-title":"An overview on application of phage display technique in immunological studies","volume":"7","author":"Rami","year":"2017","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jmb.2005.10.048","article-title":"Molecular structure of fd (f1, M13) filamentous bacteriophage refined with respect to X-ray fibre diffraction and solid-state NMR data supports specific models of phage assembly at the bacterial membrane","volume":"355","author":"Marvin","year":"2006","journal-title":"J. Mol. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pbiomolbio.2014.02.003","article-title":"Structure and assembly of filamentous bacteriophages","volume":"114","author":"Marvin","year":"2014","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14760584.2019.1651649","article-title":"The development of inovirus-associated vector vaccines using phage-display technologies","volume":"18","author":"Stern","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.vetpar.2010.04.012","article-title":"Recombinant peptides as new immunogens for the control of the bovine tick, Rhipicephalus (Boophilus) microplus","volume":"172","author":"Prudencio","year":"2010","journal-title":"Veter. Parasitol."},{"key":"ref_73","first-page":"215","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_74","unstructured":"Li, W., Drelich, A., Martinez, D.R., Gralinski, L., Chen, C., Sun, Z., Liu, X., Zhelev, D., Zhang, L., and Peterson, E.C. (2020). Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody. bioRxiv, 2020.05.13.093088."},{"key":"ref_75","first-page":"51","article-title":"Filamentous bacteriophage: Biology, phage display and nanotechnology applications","volume":"13","author":"Rakonjac","year":"2011","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1574-6976.1995.tb00184.x","article-title":"Engineering a peptide epitope display system on filamentous bacteriophage","volume":"17","author":"Perham","year":"1995","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0378-1119(96)00070-4","article-title":"New vectors for peptide display on the surface of filamentous bacteriophage","volume":"171","author":"Malik","year":"1996","journal-title":"Gene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.3390\/ijms13045179","article-title":"Filamentous bacteriophage Fd as an antigen delivery system in vaccination","volume":"13","author":"Prisco","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/jmbi.2000.3561","article-title":"Identification of natural ligands for SH2 domains from a phage display cDNA library","volume":"297","author":"Cochrane","year":"2000","journal-title":"J. Mol. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1101\/gr.861503","article-title":"Selecting open reading frames from DNA","volume":"13","author":"Zacchi","year":"2003","journal-title":"Genome Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1093\/nar\/gkq052","article-title":"Rapid interactome profiling by massive sequencing","volume":"38","author":"Sulic","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.vetimm.2003.12.009","article-title":"Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis","volume":"99","author":"Manoutcharian","year":"2004","journal-title":"Veter. Immunol. Immunopathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.vaccine.2008.03.042","article-title":"Inexpensive anti-cysticercosis vaccine: S3Pvac expressed in heat inactivated M13 filamentous phage proves effective against naturally acquired Taenia solium porcine cysticercosis","volume":"26","author":"Morales","year":"2008","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.vaccine.2018.08.011","article-title":"Phage vaccines displaying YGKDVKDLFDYAQE epitope induce protection against systemic candidiasis in mouse model","volume":"36","author":"Shi","year":"2018","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jbiotec.2015.10.001","article-title":"Humoral immune responses against gonadotropin releasing hormone elicited by immunization with phage-peptide constructs obtained via phage display","volume":"216","author":"Samoylov","year":"2015","journal-title":"J. Biotechnol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/1098612X19875831","article-title":"Phage constructs targeting gonadotropin-releasing hormone for fertility control: Evaluation in cats","volume":"22","author":"Johnson","year":"2019","journal-title":"J. Feline Med. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jviromet.2006.09.017","article-title":"Bacteriophage T4 nanoparticle capsid surface SOC and HOC bipartite display with enhanced classical swine fever virus immunogenicity: A powerful immunological approach","volume":"139","author":"Wu","year":"2007","journal-title":"J. Virol. Methods"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"12551","DOI":"10.1128\/JVI.02043-14","article-title":"Immunogenicity studies of proteins forming the T4 phage head surface","volume":"88","author":"Miernikiewicz","year":"2014","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e01926-18","DOI":"10.1128\/mBio.01926-18","article-title":"A bacteriophage T4 nanoparticle-based dual vaccine against anthrax and plague","volume":"9","author":"Tao","year":"2018","journal-title":"mBio"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00705-018-4026-0","article-title":"Suppression of angiogenesis and tumor growth by recombinant T4 phages displaying extracellular domain of vascular endothelial growth factor receptor 2","volume":"164","author":"Zuo","year":"2018","journal-title":"Arch. Virol."},{"key":"ref_91","first-page":"714","article-title":"Advances in the T7 phage display system (Review)","volume":"17","author":"Deng","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Hashemi, H., Pouyanfard, S., Bandehpour, M., Noroozbabaei, Z., Kazemi, B., Saelens, X., and Mokhtari-Azad, T. (2012). Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0045765"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7688","DOI":"10.1128\/JVI.00235-06","article-title":"Assembly of Human Immunodeficiency Virus (HIV) antigens on bacteriophage T4: A novel in vitro approach to construct multicomponent HIV vaccines","volume":"80","author":"Sathaliyawala","year":"2006","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.vetmic.2017.04.023","article-title":"Immunogenicity of T7 bacteriophage nanoparticles displaying G-H loop of foot-and-mouth disease virus (FMDV)","volume":"205","author":"Xu","year":"2017","journal-title":"Veter. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s00253-014-5521-1","article-title":"Bacteriophage lambda display systems: Developments and applications","volume":"98","author":"Nicastro","year":"2014","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e00407","DOI":"10.1016\/j.heliyon.2017.e00407","article-title":"Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma","volume":"3","author":"Iwagami","year":"2017","journal-title":"Heliyon"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1093\/nar\/gnf077","article-title":"Biotin-tagged cDNA expression libraries displayed on lambda phage: A new tool for the selection of natural protein ligands","volume":"30","author":"Ansuini","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.intimp.2013.04.027","article-title":"Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets","volume":"16","author":"Ou","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"11671","DOI":"10.3748\/wjg.v20.i33.11671","article-title":"Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection","volume":"20","author":"Bakhshinejad","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jmb.2003.09.033","article-title":"High-density functional display of proteins on bacteriophage lambda","volume":"334","author":"Gupta","year":"2003","journal-title":"J. Mol. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1016\/j.vaccine.2009.08.019","article-title":"Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes","volume":"27","author":"Gamage","year":"2009","journal-title":"Vaccine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1016\/j.vaccine.2010.07.047","article-title":"Dual expression system for assembling phage lambda display particle (LDP) vaccine to porcine Circovirus 2 (PCV2)","volume":"28","author":"Hayes","year":"2010","journal-title":"Vaccine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1016\/j.vaccine.2017.11.010","article-title":"Lambda display phage as a mucosal vaccine delivery vehicle for peptide antigens","volume":"35","author":"Gamage","year":"2017","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Hayes, S. (2019). Bacterial virus lambda gpd-fusions to cathelicidins, \u03b1- and \u03b2-defensins, and disease-specific epitopes evaluated for antimicrobial toxicity and ability to support phage display. Viruses, 11.","DOI":"10.3390\/v11090869"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"a012518","DOI":"10.1101\/cshperspect.a012518","article-title":"Therapeutic and prophylactic applications of bacteriophage components in modern medicine","volume":"4","author":"Adhya","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.4161\/hv.21703","article-title":"Phage display\u2014A powerful technique for immunotherapy","volume":"8","author":"Bazan","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.4049\/jimmunol.180.6.3719","article-title":"The use of filamentous bacteriophagefdto deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses","volume":"180","author":"Sartorius","year":"2008","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/v4040471","article-title":"Bacteriophages with the ability to degrade uropathogenic escherichia coli biofilms","volume":"4","author":"Chibeu","year":"2012","journal-title":"Viruses"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12223-019-00750-y","article-title":"Managing urinary tract infections through phage therapy: A novel approach","volume":"65","author":"Malik","year":"2019","journal-title":"Folia Microbiol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Djebara, S., Maussen, C., De Vos, D., Merabishvili, M., Damanet, B., Pang, K.W., De Leenheer, P., Strachinaru, I., Soentjens, P., and Pirnay, J.-P. (2019). Processing phage therapy requests in a brussels military hospital: Lessons identified. Viruses, 11.","DOI":"10.3390\/v11030265"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Pirnay, J.P., Verbeken, G., Ceyssens, P.J., Huys, I., De Vos, D., Ameloot, C., and Fauconnier, A. (2018). The magistral phage. Viruses, 10.","DOI":"10.3390\/v10020064"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1473-3099(18)30502-4","article-title":"Phage therapy 2.0: Where do we stand?","volume":"19","author":"Breederveld","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Pinto, A.M., Cerqueira, M.A., Ba\u00f1obre-L\u00f3pes, M., Pastrana, L.M., and Sillankorva, S. (2020). Bacteriophages for chronic wound treatment: From traditional to novel delivery systems. Viruses, 12.","DOI":"10.3390\/v12020235"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Styles, K.M., Thummeepak, R., Leungtongkam, U., Smith, S.E., Christie, G.S., Millard, A., Moat, J., Dowson, C.G., Wellington, E.M.H., and Sitthisak, S. (2020). Investigating bacteriophages targeting the opportunistic pathogen Acinetobacter baumannii. Antibiotics, 9.","DOI":"10.3390\/antibiotics9040200"},{"key":"ref_115","first-page":"129","article-title":"Alternative treatment approaches of urinary tract infections caused by uropathogenic Escherichia coli strains","volume":"66","year":"2019","journal-title":"Acta Biochim. Pol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Zalewska-Pi\u0105tek, B., and Pi\u0105tek, R. (2020). Phage therapy as a novel strategy in the treatment of urinary tract infections caused by E. Coli. Antibiotics, 9.","DOI":"10.3390\/antibiotics9060304"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3389\/fmicb.2016.01024","article-title":"Development of a phage cocktail to control proteus mirabilis catheter-associated urinary tract infections","volume":"7","author":"Melo","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.3389\/fmicb.2018.02029","article-title":"Global Environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches","volume":"9","author":"Honda","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/138920110790725410","article-title":"Phage therapy pharmacology","volume":"11","author":"Abedon","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/138920110790725401","article-title":"Phage therapy in clinical practice: Treatment of human infections","volume":"11","author":"Kutter","year":"2010","journal-title":"Curr. Pharm. Biotechnol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/4\/331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:11:17Z","timestamp":1760364677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/4\/331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":120,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["ph14040331"],"URL":"https:\/\/doi.org\/10.3390\/ph14040331","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]}}}